UofT Libraries is getting a new library services platform in January 2021.
Learn more about the change.
Search Articles
The lancet oncology, ISSN 1470-2045, 2016, Volume 17, Issue 4, pp. 425 - 439
Hematology, Oncology and Palliative Medicine | Life Sciences & Biomedicine | Oncology | Science & Technology | Piperazines - administration & dosage | Estradiol - analogs & derivatives | Pyridines - administration & dosage | Double-Blind Method | Receptor, ErbB-2 - genetics | Humans | Middle Aged | Estradiol - administration & dosage | Treatment Outcome | Breast Neoplasms - drug therapy | Neoplasm Recurrence, Local - pathology | Phosphatidylinositol 3-Kinases - genetics | Disease-Free Survival | Neoplasm Metastasis | Breast Neoplasms - genetics | Class I Phosphatidylinositol 3-Kinases | Breast Neoplasms - pathology | Adult | Female | Neoplasm Recurrence, Local - genetics | Aged | Mutation | Medical colleges | Care and treatment | Oncology, Experimental | Clinical trials | Breast cancer | Metastasis | Hormones | Research | Antineoplastic agents | Epidemiology | Antimitotic agents | Analysis | Product development | Cancer | Index Medicus
Journal Article
The lancet oncology, ISSN 1470-2045, 2016, Volume 17, Issue 3, pp. 367 - 377
Hematology, Oncology and Palliative Medicine | Life Sciences & Biomedicine | Oncology | Science & Technology | Breast Neoplasms - surgery | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Follow-Up Studies | Humans | Middle Aged | Mastectomy - methods | Receptor, ErbB-2 - metabolism | Quinolines - administration & dosage | Dose-Response Relationship, Drug | Neoplasm Invasiveness - pathology | Adult | Female | Chemotherapy, Adjuvant | Double-Blind Method | Drug Administration Schedule | Kaplan-Meier Estimate | Proportional Hazards Models | Trastuzumab - adverse effects | Treatment Outcome | Trastuzumab - administration & dosage | Breast Neoplasms - drug therapy | Disease-Free Survival | Breast Neoplasms - pathology | Internationality | Survival Analysis | Breast Neoplasms - mortality | Aged | Neoplasm Staging | Quinolines - adverse effects | Antimitotic agents | Tyrosine | Medical colleges | Care and treatment | Adjuvant treatment | Clinical trials | Product development | Breast cancer | Metastasis | College teachers | Antineoplastic agents | Cancer | Index Medicus
Journal Article
The lancet oncology, ISSN 1470-2045, 2017, Volume 18, Issue 7, pp. 904 - 916
Hematology, Oncology and Palliative Medicine | Life Sciences & Biomedicine | Oncology | Science & Technology | Estradiol - analogs & derivatives | Humans | Middle Aged | Aminopyridines - adverse effects | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Response Evaluation Criteria in Solid Tumors | Alanine Transaminase - blood | Receptors, Estrogen - analysis | Fulvestrant | Receptors, Progesterone - analysis | Breast Neoplasms - chemistry | Neoplasm Metastasis | Hyperglycemia - chemically induced | DNA, Neoplasm - blood | DNA Mutational Analysis | Exanthema - chemically induced | Postmenopause | Female | Morpholines - adverse effects | Aminopyridines - administration & dosage | Drug Eruptions - etiology | Double-Blind Method | Morpholines - administration & dosage | Estradiol - administration & dosage | Survival Rate | Signal Transduction - genetics | Breast Neoplasms - drug therapy | Phosphatidylinositol 3-Kinases - genetics | Disease-Free Survival | Retreatment | Breast Neoplasms - genetics | Class I Phosphatidylinositol 3-Kinases | Aspartate Aminotransferases - blood | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Breast Neoplasms - pathology | Aged | Biomarkers, Tumor - genetics | Receptor, ErbB-2 - analysis | Antimitotic agents | Medical colleges | Clinical trials | Product development | Breast cancer | Postmenopausal women | Hormones | Antineoplastic agents | Analysis | Index Medicus
Journal Article
The lancet oncology, ISSN 1470-2045, 2014, Volume 15, Issue 6, pp. 580 - 591
Hematology, Oncology and Palliative Medicine | Life Sciences & Biomedicine | Oncology | Science & Technology | Sirolimus - analogs & derivatives | Sirolimus - therapeutic use | Double-Blind Method | Humans | Middle Aged | Kaplan-Meier Estimate | Proportional Hazards Models | Treatment Outcome | Breast Neoplasms - drug therapy | Disease-Free Survival | Antibodies, Monoclonal, Humanized - administration & dosage | Breast Neoplasms - genetics | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Genes, erbB-2 | Aged, 80 and over | Adult | Breast Neoplasms - mortality | Female | Aged | Everolimus | Trastuzumab | Drug Resistance, Neoplasm - drug effects | Clinical trials | Breast cancer | Angiogenesis inhibitors | Analysis | Index Medicus
Journal Article
The lancet oncology, ISSN 1470-2045, 2012, Volume 13, Issue 4, pp. 345 - 352
Hematology, Oncology and Palliative Medicine | Life Sciences & Biomedicine | Oncology | Science & Technology | Aromatase Inhibitors - administration & dosage | Neoplasms, Hormone-Dependent - surgery | Breast Neoplasms - surgery | Goserelin - administration & dosage | Triazoles - administration & dosage | Triazoles - adverse effects | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Premenopause | Humans | Middle Aged | Receptor, ErbB-2 - metabolism | Breast Neoplasms - drug therapy | Tamoxifen - administration & dosage | Nitriles - administration & dosage | Breast Neoplasms - pathology | Adult | Female | Neoadjuvant Therapy | Neoplasms, Hormone-Dependent - drug therapy | Neoplasm Staging | Nitriles - adverse effects | Antimitotic agents | Menopause | Clinical trials | Product development | Breast cancer | Postmenopausal women | Tamoxifen | Antineoplastic agents | Index Medicus
Journal Article
Human pathology, ISSN 0046-8177, 2017, Volume 64, pp. 145 - 155
Pathology | Invasive ductal carcinoma with a predominant intraductal component (DICPIC) | Logistic regression analysis | Predicting invasion within DCIS | DCIS | Tumor thickness | Life Sciences & Biomedicine | Science & Technology | Immunohistochemistry | Breast Neoplasms - surgery | Multivariate Analysis | Predictive Value of Tests | Area Under Curve | Humans | Middle Aged | Breast Neoplasms - chemistry | Neoplasm Grading | Time Factors | Aged, 80 and over | Adult | Female | Retrospective Studies | Carcinoma, Intraductal, Noninfiltrating - surgery | Biomarkers, Tumor - analysis | Neoplasm Invasiveness | Risk Factors | Decision Support Techniques | Kaplan-Meier Estimate | Logistic Models | Treatment Outcome | Lymphatic Metastasis | Chi-Square Distribution | Carcinoma, Intraductal, Noninfiltrating - chemistry | Disease-Free Survival | Carcinoma, Intraductal, Noninfiltrating - pathology | Biopsy | Breast Neoplasms - pathology | ROC Curve | Aged | Receptor, ErbB-2 - analysis | Carcinoma, Ductal | Diagnosis | Metastasis | Analysis | Medical prognosis | Classification | Gangrene | Mammography | Breast cancer | Medical screening | Patients | Tumors | Index Medicus
Journal Article
The New England journal of medicine, ISSN 0028-4793, 08/2017, Volume 377, Issue 6, pp. 523 - 533
Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Humans | Middle Aged | Antineoplastic Agents - therapeutic use | Young Adult | Neoplasm Metastasis - drug therapy | Antineoplastic Agents - adverse effects | Genes, BRCA2 | Germ-Line Mutation | Adult | Female | Chemotherapy, Adjuvant | Genes, BRCA1 | Kaplan-Meier Estimate | Piperazines - therapeutic use | Poly(ADP-ribose) Polymerase Inhibitors - adverse effects | Breast Neoplasms - drug therapy | Piperazines - adverse effects | Poly(ADP-ribose) Polymerase Inhibitors - therapeutic use | Disease-Free Survival | Phthalazines - therapeutic use | Breast Neoplasms - genetics | Breast Neoplasms - mortality | Aged | Receptor, ErbB-2 | Phthalazines - adverse effects | Treatment outcome | Gene mutations | Analysis | Breast cancer | Genetic aspects | Research | Drug therapy | Medical research | Adenosine | Inhibitor drugs | Metastasis | Cancer therapies | Survival | ErbB-2 protein | Metastases | Chemotherapy | Epidermal growth factor | Ribose | Medical prognosis | Risk assessment | Antitumor activity | Mutation | Drug dosages | Deoxyribonucleic acid--DNA | Vinorelbine | Tumors | Index Medicus | Abridged Index Medicus
Journal Article
Brachytherapy, ISSN 1538-4721, 2016, Volume 15, pp. S62 - S62
Journal Article
Brachytherapy, ISSN 1538-4721, 2016, Volume 15, pp. S61 - S61
Journal Article
Journal of clinical oncology, ISSN 0732-183X, 05/2020, Volume 38, Issue 15_suppl, pp. 1000 - 1000
Journal Article
Journal of cardiology cases, ISSN 1878-5409, 2013, Volume 8, Issue 3, pp. 118 - 120
Journal Article
Cancer, ISSN 0008-543X, 03/2017, Volume 123, Issue 5, pp. 759 - 768
paclitaxel | adjuvant therapy | doxorubicin and cyclophosphamide (AC)‐taxane | docetaxel | randomized phase 3 | doxorubicin and cyclophosphamide (AC)-taxane | Anthracyclines - adverse effects | Cyclophosphamide - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Lymph Nodes - pathology | Humans | Middle Aged | Cyclophosphamide - adverse effects | Anthracyclines - administration & dosage | Adult | Female | Paclitaxel - administration & dosage | Taxoids - adverse effects | Japan | Docetaxel | Paclitaxel - adverse effects | Treatment Outcome | Lymphatic Metastasis | Breast Neoplasms - drug therapy | Disease-Free Survival | Taxoids - administration & dosage | Breast Neoplasms - pathology | Adolescent | Bridged-Ring Compounds - adverse effects | Aged | Bridged-Ring Compounds - administration & dosage | Anthracyclines | Usage | Cyclophosphamide | Paclitaxel | Clinical trials | Dosage and administration | Breast cancer | Drug therapy | Comparative analysis | Edema | Lymphatic system | Nausea | Taxane | Survival | Patients | Doxorubicin | Lymph nodes | Incidence | Confidence intervals | Randomization | Motivation | Anthracycline | Vomiting | Biopsy | Surgery | Factorial design | Cancer | Neutropenia | Lymph | Index Medicus | Abridged Index Medicus | Original
Journal Article